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Introduction
============

Androgens belong to a class of steroid hormones which serve as ligands for the androgen receptor (AR). Ligand-bound AR modulates target gene regulation via recognition of and binding to androgen response elements (AREs). Androgens and the AR play an essential role in sexual development \[[@r28]\], and can influence the regulation of overall body composition \[[@r46]\]. As an established anabolic treatment, androgen supplementation has been shown to positively influence bone \[[@r35]; [@r70]; [@r71]; [@r72]\] and skeletal muscle \[[@r9]; [@r26]; [@r68]; [@r79]\]. However, therapeutic use of androgens has been limited, due to adverse side effects including significant cardiovascular events \[[@r4]; [@r20]; [@r73]\] and potential risk for prostate hyperplasia \[[@r1]\]. The recent development of androgen-like molecules (e.g., non-steroidal AR modulators) aims to retain the beneficial influence of androgen on skeletal muscle, while circumventing undesirable cardiovascular and prostate-related side-effects. These modulators have been implicated as possible therapies in instances of skeletal muscle wasting, degeneration, and/or injury, where skeletal muscle mass is in a state of dysregulation \[[@r13]; [@r39]; [@r41]; [@r51]; [@r80]\]. While AR modulator efficacy has been widely studied, investigations of the molecular targets downstream of AR-mediated muscle mass regulation remain limited.

Regulation of skeletal muscle mass is a balance between protein synthesis and degradation \[[@r54]\]. Catabolic stimuli (e.g., mechanical unloading, starvation, disease, hormone deprivation therapy) induce muscle atrophy via protein degradation and autophagy pathways. Anabolic stimuli (e.g., mechanical loading, nutrient supplementation, hormone therapy) initiate muscle hypertrophy by increasing overall net protein balance. The remarkable regenerative capacity of skeletal muscle following injury is a clear example of coordinated systems involving both catabolic and anabolic pathways at work. Following an insult (injury) to muscle, a distinct process of tissue recovery commences involving degeneration, inflammation, remodeling and fibrosis \[[@r66], [@r67]; [@r69]\]. A pool of muscle-specific stem cells, termed satellite cells, is activated early and rapidly following muscle injury to directly aid in the recovery process. Muscle satellite cells (MSCs), originally defined on the basis of their location (situated between the sarcolemma and basal lamina of myofibers), are responsible for early growth during development and subsequently act as committed stem cells for adult skeletal muscle undergoing recovery from injury and trauma \[[@r43]\]. Adult MSCs serve as a self-renewing depot of cells aiding in the repair and growth of skeletal muscle \[[@r8]; [@r23]\]. MSCs are typically single, unfused and undifferentiated cells that have withdrawn from the cell cycle and are considered to be quiescent \[[@r2]; [@r58]\]. These cells uniformly express the transcription factor Pax7, and can be stimulated to enter the cell cycle through a range of catabolic and anabolic stimuli resulting in MSC activation. The activation event leads to MSC proliferation and eventual differentiation into myotubes, which fuse to existing myofibers, or each other, directly generating new muscle fibers. In the process of skeletal muscle regeneration, Pax7+ MSCs have been confirmed to be absolutely essential for normal regenerative myogenesis \[[@r38]; [@r49]; [@r55]\].

While the molecular mechanisms by which androgen promotes skeletal muscle regeneration are not completely understood, there is evidence that androgen-induced activation of MSCs is a critical mediator of this process \[[@r11]; [@r31]; [@r50]\]. The current manuscript identifies key molecular targets that are regulated by androgen using a novel levator ani satellite cell (LASC) *in vitro* system. In order to identify AR-specific changes in gene expression mediated in the LASC *in vitro* culture, a non-steroidal AR agonist (NARA) was utilized. This *in vitro* system identified notable target genes for AR that included HGF, IGF-1, CXCR4, FST, and GR. The changes observed *in vitro* were then validated in the levator ani (LA) perineal muscle tissue, which is highly responsive to androgen levels. Finally, these changes in gene expression were queried in a muscle injury model wherein endogenous satellite cells mediate the repair and recovery, and were found to provide strong evidence suggesting androgen-mediated effects on satellite cell activity. Collectively, these results provide novel *in vitro* and *in vivo* evidence describing the effect of androgen on skeletal muscle, while at the same time enhancing support for use of AR agonists in skeletal muscle diseases where atrophy and injury are present.

Materials and Methods
=====================

Materials
---------

Reagents and primers used for quantitative real-time PCR were from Life Technologies (Grand Island, NY). Primer catalog numbers for genes can be found in [Supplementary Material Table 1](#S1){ref-type="supplementary-material"}. The L6 rat skeletal muscle line (CRL-1458) was purchased from ATCC (Manassas, VA). For LASC (rat cell line) immunostaining, the anti-Pax7 antibody (MAB1675; R&D systems) was conjugated together with FITC (FITC Conjugation kit; Abcam ab102884). For mouse muscle IHC, the anti-Pax7 primary antibody was purchased from Abcam (Ab34360). The non-steroidal AR agonist (NARA) was synthesized at Eli Lilly & Co (Indianapolis, IN). All other materials were from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.

###### Rat levator ani (LA) muscle cells defined as novel satellite cell line distinct from mature myoblasts.

  **Genes**         **LASC (Relative Expression/GAPDH)**   **L6 (Relative Expression/GAPDH)**
  ----------------- -------------------------------------- ------------------------------------
  **Pax3**          **++ (0.0557)**                        **+ (0.0146**
  **Pax7**          **++ (0.0085)**                        **\-- (Not Detected)**
  **Myogenin**      **\-- (Not Detected)**                 **++ (.3319)**
  **MyoD**          **\-- (Not Detected)**                 **\-- (Not Detected)**
  **Desmin**        **++ (0.0052)**                        **+ (0.0003)**
  **Notch1**        **+ (0.0192)**                         **+ (0.0140)**
  **Notch3**        **+ (0.0133)**                         **++ (0.0212)**
  **HGF**           **+ (0.223)**                          **++ (0.2734)**
  **IGF1**          **+ (0.0262)**                         **++ (0.5441)**
  **Myf5**          **++ (1.300)**                         **+ (0.0003)**
  **CXCR4**         **+ (0.0275)**                         **\-- (Not Detected)**
  **Follistatin**   **++ (0.3881)**                        **+ (0.1096)**
  **Myostatin**     **\-- (Not Detected)**                 **++ (0.8634)**
  **AR**            **++ (0.3669)**                        **\-- (Not Detected)**

The Levator Ani Satellite cell (LASC) line was compared to the L6 myoblast cell line. Cells of each line were allowed to attach for 24 hours and maintained for 24 hours before being lysed for gene expression analysis. Relative mRNA expression (measured via real-time PCR) of a specific gene is represented by a plus sign (+), while no expression is indicated by minus signs (\--). A 3-fold or greater gene expression difference between cell lines is indicated by double plus signs (++). Relative mRNA expression values (normalized to GAPDH) are displayed in parentheses.

Animals
-------

Animal experiments were conducted in normal male ICR (CD-1) mice (20--30 g; Harlan, Indianapolis, IN), or male Wistar rats (3-4 months old; Harlan, Indianapolis, IN), performed with the approval of Institutional Animal Care and Use Committee and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animals were housed in a room with controlled temperature (22 ± 2°C), and a 12:12 h light-dark cycle with ad libitum access to food (TD 5001 with 0.95% calcium and 0.67% phosphorus; Teklad, Madison, WI) and water. For gonadectomy studies, animals (mice or rats) were divided into sham operated and un-castrated (Sham/Intact) or gonadectomized (GDX) groups. Animals were gonadectomized under anesthesia and the testes were bilaterally removed by scrotal incision. Animals were allowed to recover from operation and were put on their respective study at 6 weeks post surgery. Body composition was measured using Quantitative Nuclear Magnetic Resonance analysis (ECHO MRI, 3-1 Composition Analyzer; (Echo Medical Systems, Houston, TX).

NARA-treated animals
--------------------

Rats: Six weeks post GDX surgery, rats were grouped into separate treatment cohorts; Sham surgery (Veh), GDX (Veh), GDX + Androgen (NARA). The GDX+NARA animals were dosed daily with subcutaneous injections of NARA (1 mg/kg). Animal groups (n=7-8) were sacrificed at specified time points (3, 24, 48, 72 h, and 7 d) post initiation of NARA treatment. The LA muscles were isolated, weighed and frozen for future analysis.

Mice: Six weeks post GDX surgery, mice were grouped into separate treatment cohorts; Intact-Sham (non-gonadectomized, non-injury) with vehicle or NARA treatment, Intact-CTX (cardiotoxin injury) with vehicle or NARA treatment, GDX-Sham (gonadectomized, non-injury) with vehicle or NARA treatment, GDX-CTX with vehicle or NARA treatment. The NARA animals were dosed daily for 7 days with subcutaneous injections of NARA (1 mg/kg) prior to muscle injury. Animals continued daily vehicle or NARA treatment following injury and were sacrificed 4 days post injury in order to harvest gastrocnemius muscles.

Cardiotoxin injury
------------------

Six weeks post GDX surgery, mice were subjected to muscle injury by injecting 100 μL of 10 μM cardiotoxin (CTX; from naja nigricollis; Calbiochem, La Jolla, CA) solution (diluted in physiologic saline) into the right gastrocnemius muscle with a three-point injection technique as previously described \[[@r76]; [@r77]\]. The injured gastrocnemius muscles were subsequently harvested at specified time points for muscle mass, immunohistochemical and gene expression analysis.

Generation of levator ani satellite cell (LASC) line
----------------------------------------------------

The levator ani (LA) muscle tissue was isolated from rats (age 6 weeks) and minced with sterile scissors. The muscle homogenate was washed 3 times with Hank's Balanced Salt Solution (HBSS), and then digested by 100 U/mL collagenase (Invitrogen cat\# 17101---015) at 37^o^C and 5% CO~2~ for 18 h. The LA cell suspension was filtered through a sterile nylon mesh to separate the dispersed cells and tissue fragments. The suspension was washed 3 times by centrifugation in HBSS with the pellet being resuspended in DMEM/F12 (3:1) with 10% FBS culture medium. The LA cells were immortalized as previously described \[[@r37]; [@r64]\]. In brief, cells were transfected using the supernatant from Phoenix/hTERT (amphotropic packaging cell line transfected with human telomerase gene) with 10 µg/mL polybrene at 37^o^C and 5% CO~2~ for 3 h. Fresh culture medium was then placed on the cells, which were allowed to remain in culture for 24 h. The LA cells were then screened with 10 µg/mL blasticidin for 10 to 14 days. Single clones were isolated and remained in culture for 24 h. Individual clones were verified for expression of transcripts reflecting muscle satellite cells and AR expression. A single clone was selected that displayed satellite cell markers and was termed the levator ani satellite cell (LASC). A subset of cells from this clone were fixed (in 3.7% formaldehyde), permeabilized (0.1% Triton X-100). Immunofluorescence experiments were performed with the Pax7 primary antibody (10 µg/mL; R&D Systems) conjugated with a fluorescent label via the Alexa Fluor 488 protein labeling kit (Invitrogen). Nuclei were counterstained with DAPI and cells were visualized using confocal microscopy (40X magnification). All experiments were performed on LASCs with a passage number of 20 or less.

Electrical cell impedance sensing (ECIS) assay
----------------------------------------------

Cell impedance measurements were captured using the xCELLigence RTCA System (Roche Applied Science) instrument using the E-Plates 96-well device as previously described \[[@r53]\]. LASCs were seeded on a 96-well plate at a density of 5,000 cells per well (in 200 μL). Cells were allowed to attach for 24 h. The respective treatment (NARA or IGF-1) was applied in a volume of 30 μL without a media change to avoid sharp transient changes in the impedance readout. The xCELLigence RTCA System software (Roche Applied Science) measured the cell index value (which corresponds to electrical impedance) after 48 h of treatment. The data were normalized to the impedance value for each well prior to initiation of respective treatment.

Microarray analysis
-------------------

LASCs were treated with vehicle (DMSO; 0.2%) or NARA (10 nM) for 4 or 48 h. RNA was extracted using the PerfectPure RNA isolation kit (5 Prime, Gaithersburg, MD). Five μg of total RNA from each sample was labeled and hybridized to Affymetrix Rat Genome 230_2.0 microarrays according to Affymetrix protocols. Each microarray was washed and stained using an Affymetrix Fluidics Station 400 and scanned in an Affymetrix confocal GeneArray scanner. Affymetrix MAS5.0 software was used to scale data to a target intensity of 1500 and calculate transcript abundance (signal). Microarray signal intensities were generated by Affymetrix Expression Console using the MAS5 algorithm with targeted trimmed mean signal set to 1500. The gene chips were checked for quality control by their detection calls, chip pairwise correlation, and principal components analysis (PCA). Three chips were identified as outliers and excluded from analysis for obvious low correlation with and deviating on PCA plots from the rest of the chips. ANOVA t-test was carried out to test the statistical significance between groups of interest for each probe set using statistical software SAS (SAS Institute). The resultant p-values were then adjusted for multiple testing using the false discovery rate (FDR) approach by Benjamini and Hochberg \[[@r5]\]. The microarray data can be accessed at the GEO repository, accession number GSE63489. Qiagen Ingenuity Pathway Analysis (IPA) software was applied to further examine the data using an FDR cutoff of 0.2 and fold change cutoff of 1.4.

Gene expression analysis
------------------------

RNA was extracted from cells using the PerfectPure RNA isolation kit and from skeletal muscles using TRIzol reagent (Life Technologies, Grand Island, NY). Total RNAs were reverse transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). All cDNAs were assayed for genes of interest using TaqMan Gene Expression Analysis (Applied Biosystems, Carlsbad, CA) and the Assay-On-Demand primer/probe set (Life Technologies). Gene of interest mRNA levels were quantitated by determining the cycle number at which amplification detection threshold was achieved. Real-time polymerase chain reactions (rt-PCR) were performed in 20 µl reactions according to manufacturer guidelines. Samples were subjected to quantitative rt-PCR using the ABI 7900HT real-time PCR system (Life Technologies). Gene of interest values were normalized to a housekeeping gene prior to interpretation of results.

Luciferase reporter assay measuring promoter induction
------------------------------------------------------

LASCs were seeded (10,000 cells/well) and allowed to attach for 24 h, then transfected with a luciferase reporter plasmid (PGL3 Vector: Promega Cat. \# E1761) containing the appropriate promoter construct. The FST luciferase construct contained the \~1.0 kb 5' upstream region of the FST promoter (reverse primer sequence, 5'-CCCTCGAGGGGCTGCGGTCTTCCATGAATT-3'; forward primer sequence 5'-GGGTACCCCTGCAGGCTGTGGGGGAGTGG-3'). The HGF luciferase construct contained the \~1.4 kb 5' upstream region of the HGF promoter (reverse primer sequence, 5'-GGCTAGCCGATGCCGGGCTGAAAGAA-3'; forward primer sequence 5'-GGGTACCCTGCCTTTGCTGGTGGAGGTG-3'). Following 36 h, cells were treated with 10 nM of Metribolone (R1881) or 0.1% DMSO (Vehicle). Cells were subjected to lysis and luminescence was measured using a GeniosPRO instrument with substrate injection (Luciferase Reporter Gene Assay Kit; Roche, Basel, Switzerland). Values are representative of transfection experiments performed in triplicate. Relative luciferase units were measured. Putative androgen response elements (AREs) and corresponding predicted scores were determined by JASPAR database modeling \[[@r42]\].

Muscle histology
----------------

Muscle tissue samples were fixed in 10% neutral-buffered formalin, paraffin-embedded, and evaluated using H&E staining of gastrocnemius muscle sections using Aperio ImageScope software (Vista, CA). Images were acquired using digital slide scanning (ScanScope XT; Aperio). Immunofluorescence experiments were performed with anti-PAX7 (1.0 mg/mL: Abcam), followed by secondary anti-mouse Alexa Fluor488 Antibody (1:250). DAPI staining was performed using Fluoro-gel II with DAPI (Electron Microscopy Sciences, Hatfield, PA) during the coverslip process. All experiments were repeated a minimum of three times with at least five animals per group. All quantifications of Pax7 were determined using ImageScope software version 11.2.0.780 (Aperio).

Statistical analysis
--------------------

Data were expressed as means ± SEM. Differences between two groups were determined by the Student t test. One-way ANOVA was used to evaluate the effects of multiple groups. A three-way ANOVA was used to assess data in [Figure 5](#f5){ref-type="fig"}, main effects of androgen status (Intact vs GDX), injury status (sham vs. CTX), and treatment (vehicle vs. NARA), as well as interactions between androgen status, injury status, and treatment for all variables. Dunnett's or Bonferonni's post hoc t test was applied to determine the source of significant variance. A P value of ≤0.05 was considered statistically significant.

![NARA treatment augments satellite cell activation in gonadectomized mouse model following muscle injury.\
Gastrocnemius muscle from treated (NARA; 1 mg/kg/day) or untreated (Vehicle), intact or gonadectomized (GDX) mice were removed 4 days post sham or cardiotoxin (CTX) injection. **A-B.** Pax7 and MyoD relative mRNA expression levels. **C-D.** Pax7-positive cell quantifications and their representative images of immunofluorescence in gastrocnemius sections muscles 4 days after CTX injury, using an antibody specific for Pax7 (green) with the addition of DAPI (blue) staining for nuclei. Original magnification, x20. Data are expressed as means ± SEM of five mice per group. A three-way ANOVA was used to assess main effects of androgen status (Intact vs GDX), injury status (sham vs. CTX), and treatment (vehicle vs. NARA), as well as interactions between androgen status, injury status, and treatment for all variables; significance was set at P ≤0.05. \*Significantly different from corresponding vehicle group. \# Significantly different from corresponding sham group within androgen status model (Intact or GDX). † Significantly different between GDX and corresponding intact group.](nrs-13-005-g5){#f5}

Results
=======

Rat levator ani (LA) muscle cells defined as novel satellite cell line distinct from mature myoblasts
-----------------------------------------------------------------------------------------------------

Using a collagenase-based separation protocol (see Methods), a novel cell line was isolated from the LA muscle. These cells displayed morphology consistent with previously published work describing muscle satellite cells \[[@r45]; [@r48]\]. The predominant phenotype consisted of small, single nucleated cells with an elongated shape expressing Pax7 (representative cell image [Figure 1A](#f1){ref-type="fig"}). These cells were confirmed to be a novel line of muscle satellite cells, which were subsequently termed levator ani satellite cells (LASCs). RT-qPCR analysis indicated that LASCs expressed established satellite cell genes (Pax3, Pax7, Desmin, Myf5), while they lacked the expression of mature myoblast/muscle genes (myogenin, myoD and myostatin) compared to rat myoblast L6 cell line ([Table 1](#t1){ref-type="table"}). Collectively, these phenotypic and genotypic assessments provide a compelling view of the muscle satellite cell line.

![LASC response to androgen receptor agonists.\
**A.** Representative images of levator ani satellite cell (LASC) line. **B.** LASCs were treated with increasing doses of Metribolone (Met; dark circles), Met + Bicalutamide (Bic; 200 μM; gray squares), NARA (black triangles), or NARA + Bic (200 μM; grey inverted triangles). IGF-1 expression (normalized to GAPDH) was used as an indicator of an androgen response. **C-D.** LASCs seeded in 96-well Acea plates for 24 h in appropriate media were then treated with increasing doses of **C.** NARA or **D.** IGF-1, and incubated 48 h. Cell proliferation was measured over a 48 h time period and the cell impedance index was plotted. **E-G.** LASCs were seeded in 6-well plates for 24 h. Cells were then incubated with or without cycloheximide (CHX; 10 μM) for 1 h followed by 48 h treatment with Vehicle or NARA (10 nM). Relative mRNA expression of **E.** Pax7, **F.** IGF-1, **G.** HGF (normalized to β-actin) was measured via real-time PCR. Data are means ± SEM. \* p\>0.05 vs Vehicle and † p\<0.05 vs NARA, as determined by ANOVA and Dunnet's post hoc analysis.](nrs-13-005-g1){#f1}

LASCs display robust response to AR agonist
-------------------------------------------

Steroidal AR agonists (e.g., testosterone, metribolone) often display adverse effects due to cross-reactivity with other steroid hormone receptors \[[@r24]\]. Accordingly, exploration of nonsteroidal AR agonists has grown with the increasing interest in AR-mediated therapeutics. To confirm effectiveness between a steroidal AR-agonist (metribolone) versus a nonsteroidal AR-agonist (NARA) in the LASC line, we measured gene regulation of IGF-1, a well-established AR target gene. Both AR agonists displayed a dose-response relationship with comparable effectiveness at inducing IGF-1 expression ([Figure 1B](#f1){ref-type="fig"}). Inability of the non-steroidal AR agonists to be aromatized is a distinguishing and attractive trait for this class of molecule. To investigate whether our NARA demonstrated AR specificity (suggesting a nonaromatizable compound) bicalutamide was utilized as an AR antagonist. Bicalutamide (200 μM) completely inhibited NARA-mediated upregulation of IGF-1 at all doses ([Figure 1B](#f1){ref-type="fig"}), confirming AR specificity for the NARA.

Electric cell-substrate impedance sensing (ECIS) is commonly used to monitor changes in cell attachment, size, migration and/or proliferation. In order to further characterize the response of LASC to NARA, the ECIS assay was applied to measure LASC proliferation in response to increasing NARA doses. A surprising, yet consistent, decrease in LASC proliferation was observed with increasing doses of NARA, as reflected by the decreased cell impedance index ([Figure 1C](#f1){ref-type="fig"}). Morphological changes were apparent as a result of androgen stimulation, suggesting these cells were being driven to differentiate. In order to determine if the activity could be explained by increased NARA-mediated IGF-1 signaling, the ECIS assay was applied to measure LASC proliferation in response to increasing IGF-1 doses ([Figure 1D](#f1){ref-type="fig"}). Similar to NARA treatment, there was a dose-dependent decrease in the cell impendence index, consistent with a NARA-induced, IGF-1-mediated decrease in proliferation. Accordingly, the expression of IGF-1 may contribute in large part to the activation and myogenic differentiation of LASCs.

To confirm LASC myogenic differentiation capacity, LASCs were plated and treated with or without NARA in differentiation media (DM) for up to 96 h. Morphological and gene expression analysis ([Supplementary Material Figure 1](#S1){ref-type="supplementary-material"}) was performed at 6, 24, 48, 72, and 96 h post DM introduction. LASCs displayed significantly decreased levels of the classic MSC marker, Pax7, over the differentiation time course. Concurrently, LASCs presented significantly increased levels of MyoD, MyoG and Myh2. Morphologically, myotubes were visible after 72 h in differentiation media (+NARA). The NARA treatment was observed to augment the differentiation process when defined by gene expression. In NARA-treated LASCs, Pax7 was significantly decreased by 24 h (vs. 72 for Veh), while MyoD and MyoG expression increased earlier in the differentiation time course, as well (vs. Veh). Together, differentiation of the novel LASC line into myotubes was established, with NARA treatment augmenting the maturation process of these satellite cells.

Cycloheximide co-treatment was used to determine if androgen-mediated gene regulation required protein synthesis. LASCs were treated with or without NARA (10 nM) in combination with or without cycloheximide (10 μM) for 48 h. Overall, cycloheximide (CHX) inhibited androgen-mediated gene expression. The decrease in Pax7 expression with NARA treatment alone confirmed the loss of satellite cell phenotype, as LASC proliferation decreased, signifying engagement in differentiation ([Figure 1E](#f1){ref-type="fig"}). CHX did not alter IGF-1 expression in vehicle-treated LASCs, though complete inhibition of NARA-mediated IGF-1 expression was observed in CHX-treated LASCs. Of note, CHX by itself altered the regulation of PAX7 and HGF expression (vehicle-treated), suggesting that the stem cell-like feature of proliferating satellite cells, in part, required protein synthesis.

Microarray analysis of LASCs confirms androgen sensitivity and provides novel biomarkers
----------------------------------------------------------------------------------------

The LASC line proved to be a unique tool that displayed a robust response to androgen stimulation. To better understand the steps involved in active myogenesis engagement after cessation of cell proliferation, we subjected the NARA-treated (vs. vehicle; 4 or 48 h treatment) LASC mRNA to analysis with Affymetrix microarray chips. The ten genes displaying the greatest up- and down-regulation due to NARA treatment are listed in [Table 2](#t2){ref-type="table"}. Functional pathways associated with skeletal muscle growth are highlighted in [Supplementary Material Table 2](#S1){ref-type="supplementary-material"}, where 48 h of NARA treatment (vs. vehicle) significantly regulated genes involved in pathways driving skeletal muscle cell proliferation (p\<0.001; predicted inhibition), differentiation (p\<0.001; predicted activation) and hypertrophy (p\<0.001; predicted activation). To note, 4 h NARA treatment did not significantly alter these functional pathways, though did have significant effects on various other pathways (e.g., cell cycle genes upregulated). The microarray analysis confirmed activation and differentiation of LASCs within 48 h of NARA treatment, while providing a set of genes that were highly regulated; FST (+4.96 fold change), IGF1 (+4.71), NR3C1 (GR; -4.52) and CXCR4 (-9.28).

###### Top 10 up- and down-regulated genes by androgen.

                                **4 hr (vs. Vehicle)**   **48 hr (vs. Vehicle)**
  ----------------------------- ------------------------ -------------------------
  **Up-regulated *(Fold)***     RASSF9 *(4.84)*          BMPER *(12.33)*
  AFMID *(4.49)*                TFCP2L1 *(10.42)*        
  RICTOR *(4.09)*               SV2B *(10.31)*           
  SQSTN1 *(2.92)*               CRISPLD2 *(9.95)*        
  NOG *(2.81)*                  SVIL *(9.66)*            
  ERBB4 *(2.80)*                CES1 *(9.05)*            
  CEBPD *(2.73)*                TUBB4B *(8.69)*          
  MAP4K4 *(2.66)*               FGL2 *(8.43)*            
  PLEKHF2 *(2.55)*              ENPP1 *(8.21)*           
  NF2 *(2.51)*                  SULT1A1 *(6.74)*         
  **Down-Regulated *(Fold)***   NPPA *(-5.72)*           RGD1560633 *(-11.18)*
  BMP15 *(-4.58)*               **CXCR4 *(-9.28)***      
  APOC2 *(-3.47)*               PTGER3 *(-6.76)*         
  LPAR2 *(-3.08)*               TMEM26 *(-5.81)*         
  NKX2-3 *(-2.97)*              KCNA6 *(-5.58)*          
  OXT *(-2.93)*                 CPXM2 *(-5.57)*          
  NR1H2 *(-2.87)*               AP3D1 *(-5.39)*          
  FBXO32 *(-2.77)*              GTPBP1 *(-5.36)*         
  PTAFR *(-2.64)*               PTGS2 *(-5.21)*          
  TAC1 *(-2.61)*                UPK2 *(-4.86)*           

LASCs were seeded, allowed to attach 24 hours, treated with vehicle (DMSO) or NARA (10 nM) and incubated for 4 or 48 hours. Isolated cell mRNA was reverse transcribed into cDNA, labeled, and analyzed using DNA microarray. Data analysis was performed using Qiagen IPA software with cutoffs set at an FDR ≥ 0.2 and fold change ≥ 1.4. Fold change in parentheses.

Liganded AR regulates FST, CXCR4 and GR expression
--------------------------------------------------

Microarray results provided a valuable signature for androgen-mediated gene regulation from which several unique genes were highlighted as possible markers and/or mediators of muscle regeneration. To confirm LASC microarray findings, expression of follistatin (FST), C-X-C chemokine receptor 4 (CXCR4) and glucocorticoid receptor (GR) was measured (via RT-qPCR) in LASCs ([Figure 2](#f2){ref-type="fig"}). A dose-dependent increase in FST (logEC50 = 0.60 nM ± 0.17) expression, and dose-dependent decreases in CXCR4 (logEC50 = 0.35 nM ± 0.07) and GR (logEC50 = 0.31 nM ± 0.08) expression were observed. The striking response in the real time PCR results across a dose range of NARA treatment to androgen treatment reinforced the microarray findings, while at the same time providing a novel set of gene changes mediated by androgen.

![Liganded androgen receptor regulates FST, GR, and CXCR4 expression.\
LASCs were seeded and allowed to attach 24 h, then treated with increasing doses of NARA and incubated 48 h. Relative mRNA expression of **A.** CXCR4, **B.** GR, and **C.** FST (normalized to PPIB; measured via real-time PCR) displayed a dose-dependent response. Data are means ± SEM.](nrs-13-005-g2){#f2}

In order to further investigate whether androgen directly regulated our target genes, we analyzed the promoter regions for putative androgen response elements (AREs) using the JASPAR transcription factor DNA-binding model \[[@r42]\]. In addition, *in vitro* promoter induction analysis was performed using a luciferase reporter system transfected into LASCs. The \~1.0 kb upstream region of the FST promoter was found to have three predicted AREs. Robust induction of the FST promoter by 10 nM metribolone was observed ([Supplementary Material Figure 2A](#S1){ref-type="supplementary-material"}). Likewise, the \~1.4 kb upstream region of the HGF promoter was found to have predicted AREs. Induction of the HGF promoter by 10 nM metribolone was observed after 29 h of treatment ([Supplementary Material Figure 2B](#S1){ref-type="supplementary-material"}). Vehicle (0.1% DMSO) treamtent did not result in significant induction of either promoter. These results show that the upstream promoter is sufficient to drive the induction seen with AR agonism, and suggests a direct regulation of HGF and FST by AR.

In vivo androgen-mediated gene regulation in LA muscle
------------------------------------------------------

The *in vitro* results from the LASC line provided a valuable gene signature of molecular targets. We aimed to pursue *in vivo* analysis that could confirm that the androgen-mediated MSC activation and accompanying gene expression changes measured *in vitro* were physiologically relevant. A clinically-relevant model of muscle atrophy was applied to study the effect of androgen on muscle recovery. Gonadectomized (GDX) male rats were utilized to overcome the variability of circulating endogenous androgens. Daily dosing with NARA (1 mg/kg) was then performed with animals being taken for analysis at 3, 24, 48, 72 h and 7 d. The GDX treatment resulted in significantly decreased total body and LA muscle weight versus sham as a result of the androgen depletion. Supplementing with NARA did not significantly increase body weight over the 7-day treatment period, however LA tissue weight did increase significantly by day 7 ([Figure 3A](#f3){ref-type="fig"}&B).

![*In vivo* androgen-mediated gene regulation in rat LA muscle.\
Male rats (8 weeks old) underwent gonadectomy or sham surgery. Six weeks after surgery, GDX animals were dosed daily with NARA (1 mg/kg). Cohorts (n=7-8) of GDX animals were sacrificed at hour 3, 24, 48, 72 and 7 days. **A.** Body weight at time of sacrifice (grams), **B.** Levator Ani wet weight (mg), **C-G.** LA muscle relative mRNA expression of IGF-1, FST, CXCR4, HGF, and GR (normalized to β-2 microglobulin; B2M) was measured via real-time PCR. Data are means ± SEM. ANOVA indicated significant differences among groups. Dunnet's post hoc analysis set either Sham muscles or GDX (No NARA) as control and significance versus the respective group is indicated; \*p\<0.05 vs. Sham, † p\<0.05 vs GDX.](nrs-13-005-g3){#f3}

NARA-treated GDX animals provided novel *in vivo* time course results, as characterized by the gene response signature. Augmenting the LASC results, NARA treatment initially led to significant increases in expression of IGF-1 ([Figure 3C](#f3){ref-type="fig"}), FST ([Figure 3D](#f3){ref-type="fig"}), and HGF ([Figure 3F](#f3){ref-type="fig"}), while significantly decreasing expression of GR ([Figure 3G](#f3){ref-type="fig"}). Interestingly, several genes displayed a biphasic-like expression profile; daily NARA dosing induced significantly higher CXCR4 levels at the 3 h time point, however, CXCR4 levels reversed by 24 h and remained significantly decreased to the 72 h time point. Similarly, HGF levels displayed an early, yet transient increase at the 3 h point, returning to basal-like levels by 24 h. FST expression followed a similar pattern, displaying a more sustained increase at 3, 24 and 48 h, yet returning to basal-like levels by 72 h. Although GR expression did not decrease initially at 3 h, there was a sustained decrease in its expression for the duration of the time course. These *in vivo* results demonstrated that NARA-induced, AR-mediated gene expression exhibits unique profiles over time. The correlation between gene response changes *in vitro* using LASC and those seen *in vivo* suggest that satellite cells are a primary target of androgen signaling in this tissue, and that additional insight can be gained by studying the role of AR in muscle satellite cells.

Removal of androgens results in delayed recovery and altered gene expression in muscle injury model, suggesting androgen-mediated activation of satellite cells
---------------------------------------------------------------------------------------------------------------------------------------------------------------

To extend these findings from the perineal LA muscle to a typical skeletal muscle, we used a mouse model of androgen depletion (gonadectomy; GDX) combined with cardiotoxin-induced gastrocnemius muscle injury. It has been reported that recovery from cardiotoxin-mediated injury requires MSCs and involves specific steps including inflammation, tissue necrosis, macrophage infiltration, and satellite cell activation \[[@r22]; [@r76]; [@r77]\]. The mode of injury resulted in an initial increase in tissue weight, explained by acute bleeding and infiltration of cellular components driving the inflammatory response (phagocytes, monocytes, lymphocytes, etc. \[[@r17]\]). A sharp decrease in muscle weight was then observed, as severe atrophy presents during the necrosis phase of muscle repair. In androgen-normal (intact) mice, muscle recovery (based on return to sham control muscle weight) was achieved by 21 days, while androgen-null (GDX) mice required 35 days for full muscle recovery. In the androgen-normal (intact) mice, recovery following CTX (vs. control) was characterized by 1) a transient increase followed by a decrease in HGF ([Figure 4C](#f4){ref-type="fig"}) and CXCR4 ([Figure 4F](#f4){ref-type="fig"}), 2) a progressive increase in IGF-1 ([Figure 4D](#f4){ref-type="fig"}) and FST ([Figure 4E](#f4){ref-type="fig"}) and 3) an acute increase followed by an immediate normalization in TNF-α ([Figure 4G](#f4){ref-type="fig"}).

![Removal of androgens results in delayed mouse muscle recovery following insult.\
Male mice (8 weeks old) underwent gonadectomy or sham surgery. Six weeks after surgery, a cohort of mice were subjected to skeletal muscle injury via intramuscular injection of cardiotoxin (CTX; 10 µM) in the gastrocnemius muscle. Cohorts (n=7-8) of animals were sacrificed at post CTX injury at day 1, 3, 5, 7, 14, 21, 28, 35. **A.** Body weight at time of sacrifice (grams), **B.** Gastrocnemius wet weight (mg), **C-H.** Gastroc muscle relative mRNA expression of HGF, IGF-1, FST, CXCR4, and TNF-α (normalized to PPIB) was measured via real-time PCR. Data are means ± SEM. Significance (\*p\<0.05) of CTX vs. Control (within Intact or GDX) was analyzed by ANOVA and Bonferonni's posthoc analysis. **H-I.** Representative H&E cross-sectional images (20X) of myofibers and fatty infiltration in the **H.** Intact (androgen-normal) and **I.** GDX (androgen-depleted) gastrocnemius muscle at the 21 days post cardiotoxin time point.](nrs-13-005-g4){#f4}

Removal of endogenous androgen (GDX mice) resulted in delayed muscle recovery following CTX-induced muscle injury ([Figure 4B](#f4){ref-type="fig"}), as observed by muscle weight. By day 21, the injured muscles from intact (androgen-normal) mice had regained mass comparable to the sham control, suggesting complete recovery. Conversely, the injured muscles from GDX (androgen-depleted) mice did not fully recover muscle mass (vs. uninjured control) until day 35. Histological analysis (H&E) performed on muscles at 21 days post CTX injury reflected interstitial fatty infiltration in the gastrocnemius muscle from GDX mice, while the intact muscles displayed pathology consistent with healthy regenerating muscle ([Figure 4H](#f4){ref-type="fig"}). Injury in the androgen-depleted (GDX) model highlighted genes possibly regulated by androgen. Though subtle, androgen-depletion resulted in delayed upregulation of CXCR4, with androgen-normal muscle displaying a 116% increase in CTX vs. Ctrl muscle, while GDX only had a 19% (CTX vs. Ctrl) increase one day post CTX. Likewise, androgen-depletion resulted in significantly increased TNF-α levels following CTX injury, with a 304% increase (vs. Ctrl) in the GDX group and 4% decrease (vs. Ctrl) in the intact group at day 3 post CTX (see [Table 3](#t3){ref-type="table"} for further description of the percent changes between CTX versus control muscles from the intact and GDX mice). While IGF-1 and FST levels displayed little variation between intact vs. GDX groups, differential expression of HGF, CXCR4 and TNF-α provided results suggesting that gene regulation was being mediated in an androgen-specific manner in response to injury.

###### Percent change between control vs. CTX animals.

  --------------------------------------------------------------------------------------------------------------------------
  **Measurement**           **Androgen Status**        **Day 1**           **Day 3**           **Day 5**      **Day 7**
  ------------------------- -------------------------- ------------------- ------------------- -------------- --------------
  **Muscle Weight**         *[Normal (Intact)]{.ul}*   **+20%\***\         **-12%\***\         **-20.4%\***   **-16.7%\***
                                                       **(CTX \> Ctrl)**   **(CTX \< Ctrl)**                  

  *[Depleted (GDX)]{.ul}*   **+24%\***                 **-12.9%\***        **-14.3%\***        **-22.8%\***   

  **HGF**                   *[Normal (Intact)]{.ul}*   +67%                **+364%\***         **+194%\***    **+107%\***

  *[Depleted (GDX)]{.ul}*   **+163%\***                **+527%\***         **+143%\***         **+105%\***    

  **IGF-1**                 *[Normal (Intact)]{.ul}*   **-50%\***          **-43%\***          +4%            +34%

  *[Depleted (GDX)]{.ul}*   **-38%\***                 -18%                +5%                 +22%           

  **FST**                   *[Normal (Intact)]{.ul}*   **-45%\***          **-56%\***          **-28%\***     **-20%\***

  *[Depleted (GDX)]{.ul}*   **-44%\***                 **-71%\***          **-44%\***          +3%            

  **CXCR4**                 *[Normal (Intact)]{.ul}*   **+116%\***         **+176%\***         **+80%\***     **+76%\***

  *[Depleted (GDX)]{.ul}*   +19%                       **+71%\***          **+47%\***          **+106%\***    

  **TNF-α**                 *[Normal (Intact)]{.ul}*   **+1294%\***        -4%                 +8%            -18%

  *[Depleted (GDX)]{.ul}*   **+1752%\***               **+304%\***         +54%                +52%           
  --------------------------------------------------------------------------------------------------------------------------

Weight (body and muscle) and gene changes were compared between the Control versus CTX muscles in androgen-normal (intact) and androgen-depleted (GDX) animals, as displayed in [Figure 4](#f4){ref-type="fig"} (e.g., Normal Muscle Weight on Day 1 of +20% indicates CTX muscles were 20% heavier than Control muscles). \*p\>0.05; differences calculated to be significant, as shown graphically in [Figure 4](#f4){ref-type="fig"}.

NARA treatment is associated with markers of satellite cell activation following muscle injury
----------------------------------------------------------------------------------------------

Using the mouse model of androgen depletion (gonadectomy; GDX) combined with cardiotoxin (CTX)-induced gastrocnemius muscle injury, we specifically queried whether there was differential MSC activation as a result of androgen depletion in the injury model, perhaps explaining the delayed regenerative capacity. Moreover, we aimed to understand if a 7-day preventative NARA (1/mg/kg/day) treatment followed by injury (in both intact and GDX mice) could augment MSC activation. The brief 7-day NARA treatment regimen did not significantly alter gastrocnemius muscle size (data not shown). Four days post CTX injury, there was a main effect (p\<0.05) of injury (CTX vs. sham) for Pax7 and MyoD gene expression, along with Pax7-positive cells (measured via IHC) in the gastrocnemius muscle ([Figure 5](#f5){ref-type="fig"}). Furthermore, there was a significant main effect (p\<0.05) of androgen status (GDX vs. intact) for MyoD gene expression and a significant main effect (p\<0.05) of NARA treatment for MyoD gene expression and strong trend for Pax7 gene expression (p=0.083). The GDX-CTX muscle has significantly lower levels of Pax7 compared to intact-CTX, suggesting decreased MSC activation upon injury. NARA treatment in the GDX-- CTX mouse resulted in muscle expression of Pax7 similar to that of the NARA-treated intact-CTX mouse, suggesting comparable MSC activation between the groups. A similar pattern of gene expression was observed for MyoD levels; in both intact and GDX mice, NARA treatment significantly increased MyoD levels 4-days post CTX injection. Though not significant across groups, a strong trend for increased Pax7-postive cells in NARA-treated vs. vehicle-treated muscles was observedin the GDX-CTX model ([Figure 5C](#f5){ref-type="fig"}&D). Together, these data provide evidence that a lack of androgen and AR activation limits MSC activation upon muscle injury. Furthermore, AR activation, whether through an endogenous or exogenous AR agonist, augments MSC activation.

Discussion
==========

The primary goal of this study was to establish a gene response signature defining the action of androgen on satellite cell activation in order to support interpretation of clinically relevant muscle recovery and regeneration models. A novel muscle satellite cell line (levator ani satellite cells; LASCs) treated with androgen responded with dose-dependent alterations in gene expression, ultimately presenting with myogenic differentiation. Focusing on this myogenic event in LASCs, microarray analysis established a unique gene signature highlighting markers of muscle satellite cell (MSC) activation (HGF and IGF-1), migration (CXCR4), and growth (FST and GR). Biomarker expression patterns defined by the gene signature predicted androgen-mediated muscle growth in a rat model of muscle atrophy, suggesting MSC engagement in response to liganded AR. A temporal response was observed for CXCR4, FST and HGF expression during the time course of androgen-mediated muscle growth, providing further depth to the gene signature. Finally, a muscle injury model comparing animals of normal versus depleted androgen status emphasized the requirement of androgen during skeletal muscle repair, as androgen-depleted animals displayed delayed regenerative capacity. Evidence for the role of androgen in muscle regeneration was further defined by delayed CXCR4 and HGF expression in the androgen-depleted animals post injury, suggesting hampered satellite cell activation. Furthermore, a direct effect of androgen-deprivation on the inflammatory response was observed in sustained TNF-α expression along with increased fat infiltration post injury. Finally, a connection between AR agonism and Pax7 and MyoD expression in injured muscle provided evidence for androgen-mediated MSC activation. These results are the first to actively connect androgen regulation of satellite cells to muscle recovery and regeneration through a defined set of response genes (summarized in [Supplementary Material Figure 3](#S1){ref-type="supplementary-material"}).

There is strong evidence describing androgen-mediated skeletal muscle hypertrophy \[[@r32]; [@r61]; [@r62]\]. It has been suggested that this muscle hypertrophy is largely mediated via androgen actions on MSCs \[[@r19]; [@r31]; [@r62]\]. AR is expressed in MSCs and recent evidence has established these cells as androgen targets via gene expression \[[@r19]; [@r65]\] and cell growth analysis \[[@r7]; [@r33]; [@r34]; [@r63]\]. Previous studies have utilized satellite cells isolated from the androgen-responsive levator ani (LA) muscle \[[@r12]; [@r60]\] as a powerful tool to understand androgen action \[[@r7]; [@r65]\]. Analysis of NARA-treated satellite cells from the LA (LASCs) in this study confirmed a robust androgen response while delivering a novel gene signature defining the effect of an AR agonist in the myogenic activation of satellite cells. Furthermore, changes in gene expression in in NARA-treated (48 h) LASC showing increased IGF-1 and FST, and decreased CXCR4, HGF, and GR, demonstrated that androgen ultimately facilitates entry of the muscle-derived satellite cells into myogenesis.

Up to this point, the role of androgen in MSC proliferation and differentiation remains unclear and is dependent on species and the level of stem cell commitment \[[@r11]; [@r47]\]. Characterization of the LASC line using the cell electrical impedance assay showed that NARA treatment decreased cell impedance. This indicated androgen ultimately augmented LASC differentiation, expanding on previous work showing androgen may signal through IGF-1 \[[@r18]; [@r40]\]. We further demonstrated that LASCs treated with IGF-1 displayed decreased proliferation ([Figure 1C](#f1){ref-type="fig"}), akin to the NARA response. These results suggest that LASCs are ultimately being driven to differentiate, perhaps through androgen-mediated IGF-1 signaling. Likewise, the decrease in LASC Pax7 levels after 48 h of NARA treatment confirmed the loss of satellite cell genotype, endorsing activation into myogenesis. We can infer that LASC activation and proliferation occurred prior to the differentiation event based on, 1) microarray results showing NARA-mediated activation of cell cycle at the 4 h time point (vs. vehicle) and 2) previous work showing MyoD and myf5 regulation by androgen in a time-dependent manner \[[@r60]\]. However, in the LASC+CHX study, the necessity of protein synthesis in NARA-mediated IGF-1 regulation suggests a cascade of both direct and indirect mechanisms ultimately results in satellite cells differentiating. Our results suggest that this MSC differentiation process is initiated by decreased proliferation, via down regulation in HGF, and driven to differentiate, in part, via upregulation of IGF-1 and FST.

Previous work studying muscle atrophy using androgen-depleted animals re-supplemented with an AR agonist have confirmed a rescuing of muscle mass. We believe the muscle recovery and growth observed by re-supplementation is a result of the direct action of androgen on satellite cells, specifically the activation and differentiation of MSCs that replenish the GDX-induced atrophic tissue. Utilizing the gene response markers established using LASCs to characterize *in vivo* androgen gene regulation provided further insight into the possible mechanism behind the muscle mass rescuing effect of androgen re-supplementation. CXCR4, a protein known to be important in stem cell migration \[[@r52]\], was downregulated in LASCs after 48 h. However, in the rat androgen supplementation model, CXCR4 levels displayed a biphasic response with early, transient upregulation, followed by decreased expression over time. These time-dependent changes in CXCR4 may signal cycles of trafficking and differentiation of MSCs which are required to replenish the muscle tissue upon injury or atrophy-inducing conditions. Together, these results suggests that migratory machinery action in MSCs precedes differentiation, presumably to facilitate migration of activated and proliferating MSCs to the site of required growth or repair \[[@r44]\].

Interestingly, a biphasic-like response was observed in the rat NARA time course for not only CXCR4, but also HGF. This biphasic gene response has been investigated previously in models of prostate cancer \[[@r74]\] and reproduction \[[@r25]; [@r30]\]. However, to our knowledge, this is the first *in vivo* evidence showing temporal control of AR-mediated gene regulation in skeletal muscle. Along with the early and transient induction of CXCR4, an early increase in HGF was observed which likely facilitates satellite cell activation and proliferation \[[@r3]; [@r21]\]. The latter time-dependent decrease observed for HGF and CXCR4 may support a coordinated process of cell proliferation, migration and engagement in myogenic differentiation. Follistatin also displayed a unique response, with peak expression observed at 24 h and a return to basal levels thereafter. These changes may reflect an effect of androgen on the TGF-β pathway in muscle, perhaps acting to inhibit the catabolic effects of myostatin \[[@r76]\]. Growing evidence suggests that FST may mediate the effects of androgen-induced myogenic differentiation of satellite cells \[[@r7]; [@r75]\] and this commands further investigation.

To our knowledge, this is the first study to establish that the glucocorticoid receptor (GR; NR3C1 in array results) is negatively regulated by androgen action in muscle satellite cells. While both AR and GR are members of the nuclear hormone receptor superfamily, the actions of their agonists (androgen and glucocorticoid, respectively) are opposing. Glucocorticoids, signaling through the GR, have profound catabolic effects on muscle \[[@r10]; [@r14]\] via induction of several atrogenes, including atrogin-1 \[[@r56]\] and FoxO transcription factors \[[@r29]\] and MuRF-1 \[[@r57]\]. Androgens have been shown to offset the catabolic effects of liganded-GR, however limited evidence exists regarding mechanism \[[@r14]; [@r15]; [@r16]\]. Studies showing AR-mediated down regulation of GR in the CNS (hippocampus \[[@r36]\] and motor neurons \[[@r6]\]) provide possible mechanism behind AR and GR interaction. Our results provide support of this mechanism with NARA-mediated down regulation of GR in satellite cells and rat skeletal muscle. Furthermore, results from this study showing NARA-mediated acute and sustained down regulation of GR augment recent evidence describing GR down regulation in muscle after a 42 day dosing regimen with an AR-agonist \[[@r78]\]. Combined, these data provide evidence of the anti-catabolic actions of androgen and justify further investigation.

The mechanisms involved in muscle hypertrophy often overlap with those important for muscle regeneration. Limited molecular evidence exists that directly examines the association between androgen and muscle regeneration. Furthermore, muscle regeneration requires activation of muscle satellite cells, a process which we demonstrate herein is regulated by androgen. Characterization of a clinically relevant model of muscle injury and repair using the gene response signature provided an improved understanding of muscle regeneration. The mode of injury (3-point injection of cardiotoxin) has been shown to be very efficient in recapitulating the specific pathologies associated with muscle trauma within the entire muscle (e.g., inflammation, tissue necrosis, macrophage infiltration, and satellite cell activation) \[[@r22]; [@r76]; [@r77]\]. A thorough description of muscle regeneration was achieved in the androgen normal animals with transient increases observed in HGF and CXCR4 expression. Similar to the rat muscle growth (re-supplementation) model, we believe HGF increases seen in the injury model provided the activation signal for satellite cells. Furthermore, CXCR4 likely initiated chemotactic signals for guiding the movement of activated satellite cells to the site of injury. Concurrently, IGF-1 expression was observed to be significantly lower immediately following injury (vs. Control), though by day 7 it trended higher (vs control), suggesting an initial delay in the MSC differentiation signal. Likewise, FST expression was initially decreased (vs. control), though it gradually recovered expression levels comparable to controls. Recent evidence indicates FST may control inflammation during the regeneration process \[[@r76]\], and therefore this initial down regulation may be critical for the pro-inflammatory signaling needed for proper muscle repair. The significant TNF-α increase observed on day 1 clearly represented the pro-inflammatory response, which then subsided as the muscle switched to an anti-inflammatory, pro-regeneration program.

With our understanding of muscle regeneration under androgen normal status, we aimed to better understand its direct role. Given that aging and other disease states are characterized by inadequate circulating androgen levels, an understanding of muscle recovery in the absence of androgen is also critical. Crucial knowledge is obtained in studying the effect of androgen via supplementation, but there is also great value to be derived from investigating models of androgen depletion. Using a clinically relevant model, this study showed removal of androgens (via gonadectomy) resulted in delayed muscle recovery and regeneration. The gene expression signature derived from LASCs was modified in androgen-null mice upon muscle insult and the regeneration process. While FST and IGF-1 signaling between WT and GDX appears consistent regardless of androgen-status, the initial lack of CXCR4 response in GDX mice suggests impaired motility of satellite cells to the site of injury. Interestingly HGF expression was greater in the GDX vs. WT mice, suggesting overcompensation for the lack of satellite cell response (i.e. migration) to the site of injury. The sustained increase in TNF-α expression past day 3 and into day 5, indicated that the delayed degeneration may be partly attributable to increased inflammation derived from sustained fatty infiltration. Likewise, histology of the androgen-depleted muscle highlighted increased fat infiltration. This warrants further investigation regarding androgen action on inflammatory pathways and associated cells (e.g. neutrophils, macrophages, and FAPs).

Previous work from the Bhasin lab \[[@r59]\] has shown that testosterone (T) supplementation in orchidectomized mice resulted in increased number, and larger, embryonic-MyHC^+^ fibers 4 days post injury. Concurrently, an increase in BrdU^+^/NCAM^+^ myoblasts was observed at 4 days post injury. However, by 9 days, there were no differences in regeneration markers observed between vehicle- and T-treated, suggesting the effects of androgen signaling occur during the early stages of regeneration, thereby supporting enhanced recovery. In order to ultimately confirm the connection between androgen signaling and MSCs in the early phases of muscle regeneration, a NARA-treated injury model was utilized in our studies. The results ([Figure 5](#f5){ref-type="fig"}) suggest that androgen signaling indeed activates satellite cell proliferation early in the injury response. The NARA-driven augmentation in Pax7 and MyoD mRNA levels in GDX-CTX vs. intact-CTX animals confirms the early role of androgen signaling during regeneration. Based on the *in vitro* and *in vivo* analysis provided herein, the described androgen-driven increase in MSC proliferation would yield to amplified differentiation, ultimately supporting enhanced regeneration.

Our approach to developing a gene signature of biomarkers for androgen-mediated activation of satellite cells has notable advantages and limitations. We utilized a novel *in vitro* system in conjunction with *in vivo* models to understand examples of disease (muscle atrophy and injury). Nonetheless, inherent limitations with cultured satellite cell lines not displaying a true quiescent state is an unavoidable caveat when working with these cells ex vivo. In addition, conclusions from *in vivo* evidence were obtained using separate muscles, the perineal levator ani (LA) and gastrocnemius. *In vivo*, these muscles have differing functional demands. Like other muscle groups (e.g., hindlimb vs. forelimb), they display differing response to stimuli (e.g., denervation, injury, hormonal stimulation). *In vivo*, the response to androgen is greater in the LA versus the gastrocnemius \[[@r27]\], though the reasons for this remain poorly understood. However, Braga et al. \[[@r7]\] demonstrated that MSCs isolated from these respective muscles had a similar response to androgen stimulation *in vitro*. The discrepancy between *in vivo* and *in vitro* results in that study, along with those seen in the current analysis (LASC and LA vs. gastrocnemius results), likely has multiple explanatory factors including neural and vascular inputs, and/or cell-cell interactions.

In summary, this paper provides novel insight by establishing a signature of androgen-mediated gene regulation in 1) muscle satellite cells, 2) an *in vivo* model of androgen-mediated muscle recovery and growth, and 3) an *in vivo* model of muscle regeneration. Based on our findings, we propose a mechanism of androgen action in muscle regeneration which begins with increased satellite cell activation, proliferation and mobilization driven by increases in HGF, IGF-1, FST, and CXCR4. The androgen-mediated differentiation of satellite cells occurs in a time-dependent manner and is driven by decreases in HGF and increases in IGF-1, FST and CXCR4. Satellite cell engagement into myogenesis and incorporation into muscle follows, along with pro-anabolic, anti-catabolic and anti-inflammatory actions driven, in part, by androgen-mediated decreases in HGF, CXCR4, GR, and TNF-α, along with increases in IGF-1 and FST. The gene signature described can be utilized to further understand androgen action in translational applications of muscle regeneration.
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